(Q65342055)

English

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC) (English)

0 references

country

United States of America

0 references

start time

21 July 2016

0 references

end time

1 June 2019

0 references

number of participants

54

0 references

research intervention

paclitaxel

0 references

clinical trial phase

phase I clinical trial

0 references

research site

Knight Cancer Institute

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02503358

0 references

(Q65342055)

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)